Animal experiments were performed in compliance with a project licence
issued under the Animals (Scientific Procedures) Act of 1986. Protocols were
approved by the Cancer Research UK, Cambridge Institute Animal Welfare and
Ethical Review Body.
Colo205 or MDA-MB-231 cells (5 × 106) were resuspended
in 0.2 mL PBS or a 50:50 mix of Matrigel (Corning, NY, USA) and complete DMEM,
respectively, and implanted subcutaneously in the flanks of female BALB/c
nu/nu mice (Charles River, Wilmington, MA). Tumors were
imaged when they reached ~0.8 cm3. For imaging mice were
fasted for 6 – 8 h (19 (link)) and kept
in a warmed chamber (32ºC) for 1 h prior to induction of anesthesia using
1 – 2.5 % isoflurane (Isoflo, Abbotts Laboratories Ltd, Maidenhead, UK)
in a 50:50 mix of air (1 L/min) and oxygen (1 L/min). MEDI3039, a TRAIL agonist,
(Medimmune, Cambridge, UK) was administered intravenously (i.v.) at 0.4 mg/kg
(17 ,20 (link)).
issued under the Animals (Scientific Procedures) Act of 1986. Protocols were
approved by the Cancer Research UK, Cambridge Institute Animal Welfare and
Ethical Review Body.
Colo205 or MDA-MB-231 cells (5 × 106) were resuspended
in 0.2 mL PBS or a 50:50 mix of Matrigel (Corning, NY, USA) and complete DMEM,
respectively, and implanted subcutaneously in the flanks of female BALB/c
nu/nu mice (Charles River, Wilmington, MA). Tumors were
imaged when they reached ~0.8 cm3. For imaging mice were
fasted for 6 – 8 h (19 (link)) and kept
in a warmed chamber (32ºC) for 1 h prior to induction of anesthesia using
1 – 2.5 % isoflurane (Isoflo, Abbotts Laboratories Ltd, Maidenhead, UK)
in a 50:50 mix of air (1 L/min) and oxygen (1 L/min). MEDI3039, a TRAIL agonist,
(Medimmune, Cambridge, UK) was administered intravenously (i.v.) at 0.4 mg/kg
(17 ,20 (link)).
